<DOC>
	<DOCNO>NCT00003259</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness vinorelbine treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Vinorelbine Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy vinorelbine patient metastatic hormone-resistant prostate cancer . II . Evaluate toxicity vinorelbine patient . III . Evaluate quality life patient , correlate quality life PSA response . OUTLINE : Patients receive 5-10 minute intravenous infusion vinorelbine day 1 day 8 21-day course . Patients stabilization disease , partial response , complete response , receive maximum 12 course treatment . Patients show disease progression severe toxic side effect discontinue treatment . Quality life pain assess prior treatment , day 1 8 course , end treatment . Patients follow every 3 month disease progression . PROJECTED ACCRUAL : A total 14-40 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven metastatic stage IV prostate cancer Proven hormonal resistance Measurable evaluable disease PSA least 3 time upper limit normal No leptomeningeal brain metastasis PATIENT CHARACTERISTICS : Age : 18 85 Performance status : WHO 02 Life expectancy : Greater 12 week Hematopoietic : WBC least 3500/mm3 OR Granulocyte count least 2000/mm3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Other : No acute severe infection No neoplastic disease except curatively treat basal cell squamous cell carcinoma skin , relapse free 5 year curative treatment neoplasm PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytostatic chemotherapy Endocrine therapy : At least 1 month since antiandrogens Prior hormonal therapy require Radiotherapy : No radiotherapy within past 4 week No radiotherapy lesion use evaluate activity study drug Surgery : Prior orchiectomy allow Other : No investigational drug last month No prior therapy cytostatic agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IV prostate cancer</keyword>
</DOC>